ACTICOR BIOTECH

Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

Regulatory News:

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including stroke, announces the presentation, on Wednesday, May 15, 2024 during the opening session of the 10^th European Stroke Organisation Conference (ESOC), of the phase 2/3 study results, ACTISAVE, in the treatment of acute ischemic stroke.

On this occasion, Professor Martin Köhrmann, M.D., PhD., Coordinator Investigator of the ACTISAVE study, presented the main results of the study during the opening session of the conference "Official welcome & Large Clinical Trial": "ACTISAVE Clinical Trial: Efficacy and Safety of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy." He also highlighted the differences between the ACTIMIS and ACTISAVE studies in terms of patient population.

Dr. Martin Köhrmann, M.D., PhD., Coordinator Investigator of the ACTISAVE study, stated: "The analysis of the phase 2/3 ACTISAVE study in the treatment of acute ischemic stroke did not demonstrate, in the overall population, the efficacy of glenzocimab on the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) 90 days after stroke, nor on the secondary endpoint, the proportion of patients returning to life without disability (mRS 0-2). However, a trend was observed in the proportion of patients returning to normal life (mRS 0-1), especially for patients with complete recanalization after thrombectomy (eTICI score 3). These data encourage us to search for patient subpopulations among whom an advantage of glenzocimab may be demonstrated, as its favorable safety profile remains confirmed in this study."

Gilles Avenard, Chief Executive Officer, developed: "We are faced with results that challenge our initial expectations, but the further analysis of the study data on certain subgroups is promising. Glenzocimab has shown beneficial effects in certain patient subgroups that warrant further exploration, allowing us to consider continuing discussions with the pharmaceutical groups with whom we are in contact. These data encourage us to refine and potentially redefine the positioning of glenzocimab in the treatment of strokes."